

BD Appoints Tim Patz as Worldwide President of Advanced Patient Monitoring

FRANKLIN LAKES, N.J. (Jan. 21, 2025) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Tim Patz has been named worldwide president of BD's Advanced Patient Monitoring (APM) business unit, effective immediately.

In this role, Patz will be responsible for driving APM's commercial strategy, industry leading innovation and R&D initiatives, operational and quality excellence, while supporting the completion of the integration of APM into BD. He will be based out of APM's headquarters in Irvine, Calif. and report to Mike Garrison, executive vice president and president of the BD Medical Segment.

"Tim brings decades of industry experience, including 20 years at APM, with a proven track record of delivering results and driving growth globally," said Garrison. "His leadership and patient-first approach will be critical as we complete the integration of APM and continue to launch innovative solutions that are transforming patient care."

Since 2024, Patz has served as senior vice president for APM Greater Asia, its second largest region.

Prior to that Tim led U.S. Sales and Marketing for APM overseeing its largest region and a team of more than 180 associates. Since joining APM in 2005 Tim has served in a variety of leadership roles in Sales and Marketing that contributed to consistent revenue growth and increased customer engagement, while leading multiple product launches each year.

Tim holds a Bachelor of Science in Material Science & Engineering from the University of Illinois Urbana-Champaign, a Master of Science in Bioengineering from the Georgia Institute of Technology and an MBA from The University of California, Irvine.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit [bd.com](https://www.bd.com) or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) [@BDandCo](https://twitter.com/BDandCo) or Instagram [@becton_dickinson](https://www.instagram.com/becton_dickinson).

Contacts:

Media:

Fallon McLoughlin
BD Corporate Communications
201.258.0361
Fallon.McLoughlin@bd.com

Investors:

Adam Reiffe
BD Investor Relations
201.847.6927
adam.reiffe@bd.com

Additional assets available online:  [Photos \(1\)](#)

<https://news.bd.com/2025-01-22-BD-Appoints-Tim-Patz-as-Worldwide-President-of-Advanced-Patient-Monitoring>